ArticleFrontiers in immunology2023
Impact of endogenous glucocorticoid on response to immune checkpoint blockade in patients with advanced cancer.
Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 20 citations in OpenAlex.
- Association of baseline hormone levels with outcomes of first-line immunotherapy in extensive-stage small cell lung cancer.Translational lung cancer research · 2026Article
- Endogenous glucocorticoids and glucocorticoid receptor signaling: Dual regulators of PD-1/PD-L1 immunotherapy efficacy in the tumor microenvironment.Chinese medical journal · 2026Review
- Sustained metabolic response in metastatic melanoma after intraperitoneal ozone therapy: a case report.AME case reports · 2026Article
- Long-Term Neuroimaging Findings in a Murine Model of Human Extraparenchymal Neurocysticercosis.ACS infectious diseases · 2025Article
- Organ-specific immune-related adverse events and prognosis in cancer patients receiving immune checkpoint inhibitors.BMC cancer · 2025Article
- Pre-treatment endocrine-nutritional signatures predict clinical benefit from PD-1/PD-L1 blockade in hematologic malignancies.Frontiers in nutrition · 2025Review
- The effect of baseline versus early glucocorticoid use on immune checkpoint inhibitor efficacy in patients with advanced NSCLC.Frontiers in oncology · 2025Article
- Association between emotional distress and the efficacy of advanced gastric cancer patients undergoing treatment with immune checkpoint inhibitors: a cohort study and propensity score matching study.Frontiers in oncology · 2025Article
- Dissociated response and treatment outcome with immune checkpoint blockade in advanced cancer.Scientific reports · 2024Article
- Subclone from CT26 resistant to anti-PD-1 therapy associated with increased expression of genes related to glucocorticoids.Translational oncology · 2024Article
- Histological sarcomatoid transformation in a lung adenocarcinoma patient following immune checkpoint blockade.Therapeutic advances in medical oncology · 2024Article
- Mononuclear cell composition and activation in blood and mucosal tissue of eosinophilic esophagitis.Frontiers in immunology · 2024Article
- Prognostic biomarkers for immunotherapy in esophageal cancer.Frontiers in immunology · 2024Review
- Glucocorticoid Receptor Signaling in NSCLC: Mechanistic Aspects and Therapeutic Perspectives.Biomolecules · 2023Article
- Investigating the crosstalk between chronic stress and immune cells: implications for enhanced cancer therapy.Frontiers in neuroscience · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Previous studies indicate that exogenous use of glucocorticoid (GC) affects immune checkpoint inhibitor (ICI) efficacy. However, there is a paucity of clinical data evaluating the direct impact of endogenous GC on the efficacy for cancer patients with immune checkpoint blockade. Methods: We first compared the endogenous circulating GC levels in healthy individuals and patients with cancer. We next retrospectively reviewed patients with advanced cancer with PD-1/PD-L1 inhibitor alone or combination therapy in a single center. The effects of baseline circulating GC levels on objective response rate (ORR), durable clinical benefit (DCB), progression-free survival (PFS), and overall survival (OS) were analyzed. The association of the endogenous GC levels with circulating lymphocytes, cytokines levels, and neutrophil to lymphocyte ratio, and tumor infiltrating immune cells, were systematically analyzed. Results: The endogenous GC levels in advanced cancer patients were higher than those in early-stage cancer patients as well as healthy people. In the advanced cancer cohort with immune checkpoint blockade (n=130), patients with high baseline endogenous GC levels (n=80) had a significantly reduced ORR (10.0% Conclusion: Baseline endogenous GC increase executes a comprehensive negative effect on immunosurveillance and response to immunotherapy in real-world cancer patients accompanied with cancer progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.